PRKDC and neoplasm: A further substance used in the present study is PI-103, a novel synthetic small molecule of the pyridofuropyrimidine class, which is a potent and selective inhibitor of class I PI3K [32], mTOR and DNA-PK with therapeutic activity against a range of human tumor xenografts [33].